Antithrombotic drugs in cardiovascular medicine: a year in review

Area of Science:

• Cardiology
• Pharmacology
• Clinical Trials

Background:

• Cardiovascular diseases remain a leading cause of mortality worldwide.
• Antithrombotic therapy is crucial for managing and preventing thrombotic events in cardiovascular diseases.
• Recent advancements focus on optimizing antithrombotic strategies to balance efficacy and safety.

Purpose of the Study:

• To review the latest randomized clinical trials on antithrombotic drugs for cardiovascular diseases.
• To summarize key findings from 2017 clinical trials in antithrombotic therapy.
• To provide an updated perspective on antithrombotic drug efficacy and safety.

Main Methods:

• Systematic review of randomized clinical trials published in 2017.
• Analysis of trial data focusing on antithrombotic drug efficacy and safety.
• Inclusion of registry-based trials and safety trials for comprehensive insights.

Main Results:

• Low-dose anti-Xa plus aspirin demonstrated superior efficacy over monotherapy in stable atherosclerotic disease, despite increased bleeding.
• Heparin and bivalirudin showed comparable efficacy and safety in coronary interventions.
• Dual antithrombotic therapy reduced bleeding risk post-coronary intervention compared to triple therapy.
• Early evidence suggests single antiplatelet therapy may be noninferior to dual therapy post-transcatheter aortic valve replacement with improved safety.

Conclusions:

• Optimizing antithrombotic therapy requires careful consideration of patient population and procedural context.
• Emerging evidence supports refined strategies for antithrombotic use in stable disease, coronary interventions, and post-transcatheter aortic valve replacement.
• Future research should focus on larger trials to confirm efficacy and refine safety profiles of novel antithrombotic regimens.